

Sorafenib-associated hand-foot syndrome treated with topical calcipotriol



Serkan Demirkan, MD,^a Özgür Gündüz, MD,^a and Tuba Devrim, MD^b
Kirikkale, Turkey

Key words: calcipotriol; hand-foot syndrome; hepatitis; hepatocellular carcinoma; sorafenib; sorafenib-associated hand-foot syndrome; treatment.

INTRODUCTION

Sorafenib is a multitargeted potent antiangiogenic tyrosine kinase inhibitor.¹ Sorafenib has antiproliferative and antineoplastic effects in addition to antiangiogenic effects.² According to research, the use of sorafenib is effective in the treatment of advanced hepatocellular carcinoma.^{3,4} However, sorafenib has several side effects including hand-foot skin reaction, alopecia, and Stevens-Johnson syndrome.^{5,6}

Dermatologic side effects are the most common side effects of sorafenib, accounting for more than 10%. The most common ones are maculopapular exanthema, hand-foot syndrome, facial erythema, xerosis, and alopecia.⁷ These side effects are usually mild to moderate in severity and may reduce with appropriate therapy, dose reduction, or discontinuation of sorafenib treatment.⁸

The sorafenib-associated hand-foot syndrome is characterized by symmetric painful erythematous plaques in the palmoplantar areas, which include the dorsum of hands and feet and periungual areas. Vesicles and peeling may occur in severe cases. These patients may complain of a tingling sensation, intolerance of contact with hot objects, difficulty walking, and difficulty holding objects. Histopathologic examination finds epidermal hyperplasia, nonspecific inflammatory cell infiltration, and dilate dermal veins in the dermis.⁹

The following treatment is recommended in patients with sorafenib-associated hand foot syndrome: moisturizers, topical or systemic steroids, tazarotene 0.1% cream, nicotine patch, vitamin E, pyridoxine, and cyclooxygenase inhibitor 2 for severe reactions.^{10,11}

Here we present our treatment experience in a patient with grade 3 sorafenib-associated hand foot syndrome.

CASE

We present the case of a 70-year-old man with chronic hepatitis B infection for 13 years and advanced hepatocellular carcinoma for a year. This patient started using sorafenib 1 year ago because of hepatocellular carcinoma (tablets, 800 mg/d [2 × 400, mg]). In the second month of the therapy, he complained of thickening and darkening of dorsum of the hands and the feet, tingling sensation, and intolerance of contact with hot objects. On physical examination, hyperkeratosis and warty protrusions were noted on palms and dorsum of hands (Fig 1, A and B) and feet (Fig 2, A). There were no other lesions elsewhere on the skin or mucous membranes. In addition, there were no associated systemic symptoms. On histopathologic examination, epidermal hyperplasia, papillomatosis, and hyperkeratosis were observed (Fig 3). Clinicopathologic correlation confirmed the diagnosis as sorafenib-related hand-foot syndrome, and because it interfered with normal activities, its severity was documented as grade 3. The patient was prescribed topical calcipotriol cream, and the lesions decreased within 2 weeks of treatment without discontinuing the use of sorafenib (Fig 1, C and D and Fig 2, B).

DISCUSSION AND CONCLUSION

In a phase 2 study, 93% of patients with renal cell carcinoma receiving 2 doses of 400 mg/d of sorafenib had dermatologic findings including rash and

From the Departments of Dermatology and Venerology^a and Pathology,^b Kirikkale University Faculty of Medicine.

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Serkan Demirkan, MD, Kirikkale University Faculty of Medicine, Department of Dermatology and Venerology, Yenisehir District, Tahsin Duru Avenue, No: 14, Yehsihan, Kirikkale, Turkey. E-mail: serkan.demirkan@yahoo.com.tr.

JAAD Case Reports 2017;3:354-7.

2352-5126

© 2017 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.jdc.2017.03.017>



Fig 1. Sorafenib-associated hand-foot syndrome. **A** and **B**, Hyperkeratosis and warty protrusions on palms and dorsum of hands. **C** and **D**, Total disappearance of the lesions after 2 weeks.

desquamation (66%), hand-foot skin reaction (62%), and alopecia (53%).¹² Most of these symptoms were graded between 1 and 2 in severity; however, only 17% had grade 3 or 4 severity.⁷ In a meta-analysis of patients using sorafenib, the frequency of hand-foot syndrome was 33%. Severe hand-foot reaction rate was found to be 8.9%.¹³ Dose-dependent occurrence of the symptoms of sorafenib-associated hand-foot syndrome indicates that sorafenib is directly toxic to the skin.¹⁴ Classical palmoplantar erythrodisesthesia seen with chemotherapeutic agents such as capecitabine may be difficult to distinguish from hand-foot syndrome induced by sorafenib.¹⁵ Sorafenib-induced hand-foot syndrome is usually less severe and more localized and often more hyperkeratotic.⁷ Classical erythrodisesthesia lesions caused by chemotherapeutics often present on less-pressure-exposed areas with diffuse lesions, whereas some patients using sorafenib may present with hyperkeratotic plaques at pressure-exposed areas only. The

severity of sorafenib-associated hand-foot syndrome is determined by the National Cancer Institute Cancer Therapy Evaluation Program.¹⁶ Treatment of grade 1 and grade 2 hand-foot syndrome is not recommended except for preventive measures and moisturizers. Topical or systemic treatments are recommended in grade 3 and grade 4 sorafenib-associated hand-foot syndrome.¹⁶

Patients and physicians should be aware of prevention and management of sorafenib-related hand-foot syndrome. Symptomatic treatments should be given for grade 3 sorafenib-associated hand-foot syndrome. The sorafenib dose should be reduced to 400 mg/d for at least 7 days and up to 28 days in grade 2 sorafenib-associated hand-foot syndrome. If the symptoms do not disappear or reduce to grade 1, the treatment should be discontinued for at least 7 days until the severity is reduced to grade 1 or until the symptoms disappear. After interruption of treatment, the daily sorafenib dose should be



Fig 2. Sorafenib-associated hand-foot syndrome. **A**, Prominent hyperkeratotic warty protrusions on toes. **B**, Partial remission of the lesions after 2 weeks.

restarted at a dose no higher than 400 mg. If the absence of toxicity persists or the toxicity intensity does not exceed grade 1, the full dose may be given, which is 400 mg twice daily. If the severity of hand-foot syndrome caused by sorafenib is grade 3, sorafenib treatment should be interrupted for minimum of 1 week until symptom severity is grade 0 or 1. The dose should be resumed at 400 mg daily. If the symptom severity continues to be grade 0 or 1, the dose can be increased to 400 mg twice a day, which is the full dose, after a minimum of 7 days. If grade 3 symptoms are observed 3 times, the sorafenib therapy should be discontinued.¹⁷ This protocol leads to rapid regression of symptoms. However, in some cases, when sorafenib therapy is restarted treatment can be continued without severe sorafenib-associated hand-foot syndrome.¹⁴

It is proposed by Robert et al⁷ that hands and feet should be kept away from water and should avoid tight clothing, friction, and activities that would expose them to hard contact to objects. It is

recommended to wear soft-bottomed and open shoes during treatment and use alcohol-free moisturizers immediately after bathing. Pedicure or pumice stone can be used in individuals with plantar hyperkeratosis.⁷

Petroleum gels and humectants may be used for sorafenib-associated hand-foot syndrome. Topical agents containing urea and salicylic acid may be helpful for hyperkeratotic lesions.⁷ Topical steroids can be used under medical supervision to reduce inflammation, pain, and erythema. Analgesics, pregabalin, and topical lidocaine may be used to reduce pain.¹⁰

Calcipotriol binds to the vitamin D receptors and inhibits keratinocyte proliferation and converts the differentiation into normal course.¹⁸ In this perspective, we thought that calcipotriol may be beneficial in the sorafenib-associated hand-foot syndrome. In light of this case report, treatment with calcipotriol was successful. Calcipotriol may be a good therapeutic agent in severe or nonsevere




Fig 3. Epidermal hyperplasia, papillomatosis, and hyperkeratosis in epidermis (Hematoxylin-eosin stain; original magnification: $\times 10$.)

sorafenib-associated hand-foot syndrome. In addition, calcipotriol may relieve symptoms of sorafenib-associated hand-foot syndrome while continuing the treatment with sorafenib.

REFERENCES

1. Finn RS. Drug therapy: sorafenib. *Hepatology*. 2010;51:1843-1849.
2. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. *J Clin Oncol*. 2005;23:965-972.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. *Lancet Oncol*. 2009;10:25-34.
5. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Br J Dermatol*. 2009;161:1045-1051.
6. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. *Dermatol Ther*. 2011;24:396-400.
7. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. *J Am Acad Dermatol*. 2009;60:299-305.
8. Ishak RS, Aad SA, Kyei A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. *Crit Rev Oncol Hematol*. 2014;90:152-164.
9. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous side effects of sorafenib, a novel multikinase inhibitor. *Arch Dermatol*. 2008;144:886-892.
10. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist*. 2008;13:1001-1011.
11. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. *Can Urol Assoc J*. 2007;1:41-54.
12. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol*. 2006;24:2505-2512.
13. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. *Acta Oncol*. 2008;47:176-186.
14. Robert C, Escudier B. Cutaneous side effects of multikinase inhibitors used in renal cell cancer. *Oncol News* 2007. Available from: URL: http://cancernetwork.com/eLearning/200705_renal/index.html. Accessed 2007.
15. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmarplantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management. *Am J Clin Dermatol*. 2000;1:225-234.
16. National Cancer Institute. Common terminology criteria for adverse events v3.0. Available from: URL: http://www.ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae3.pdf. Accessed February 12, 2011.
17. Bayer Pharmaceuticals Corporation. Nexavar full prescribing information. Available from: URL: <http://www.univgraph.com/bayer/inserts/nexavar.pdf>. Accessed 2007.
18. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol*. 2009;60:643-659.